Table 2

Effects of alogliptin on IMT

nAlogliptin treatment groupnConventional treatment groupTreatment effect (alogliptin-conventional treatment)P value between groups
Mean change (95% CI)P value
Common mean IMT
 Baseline (mm)1610.83 ± 0.15 1610.83 ± 0.17 0.87
 52 weeks (mm)1520.79 ± 0.14 1570.82 ± 0.16 0.18
 104 weeks (mm)1510.80 ± 0.16 1530.84 ± 0.18 0.052
 Mean change (SEM)
  52 weeks−0.029 (0.009)#−0.012 (0.009)−0.017 (−0.042, 0.007) 0.17
  104 weeks−0.026 (0.009)#0.005 (0.009)−0.030 (−0.057, −0.004) 0.022
Right maximum IMT
 Baseline (mm)1611.04 ± 0.32 1611.03 ± 0.26 0.77
 52 weeks (mm)1520.97 ± 0.23 1571.02 ± 0.30 0.099
 104 weeks (mm)1510.99 ± 0.27 1531.04 ± 0.30 0.10
 Mean change (SEM)
  52 weeks−0.062 (0.019)#−0.008 (0.018)−0.053 (−0.105, −0.002) 0.041
  104 weeks−0.045 (0.018)*0.011 (0.017)−0.056 (−0.105, −0.007) 0.025
Left maximum IMT
 Baseline (mm)1611.09 ± 0.33 1611.10 ± 0.42 0.72
 52 weeks (mm)1531.05 ± 0.37 1571.08 ± 0.36 0.50
 104 weeks (mm)1511.01 ± 0.28 1531.10 ± 0.40 0.032
 Mean change (SEM)
  52 weeks−0.040 (0.019)*−0.031 (0.019)−0.009 (−0.062, 0.043) 0.72
  104 weeks−0.079 (0.018)§−0.015 (0.018)−0.064 (−0.114, −0.014)0.013
  • Data are mean ± SD unless otherwise stated. Comparisons of IMTs during treatment with those at baseline were performed by one-sample t test based on a mixed-effects model for repeated measures. Differences in IMT between groups at each point were analyzed by the Student t test. Differences in Δchange in IMT from baseline at 52 and 104 weeks between groups at each point (treatment effect) were analyzed with mixed-effects model for repeated measures. Treatment group, week, interactions between treatment group and week, and baseline IMT were included as fixed effects.

  • *P < 0.05;

  • #P < 0.01;

  • §P < 0.001.